Australia markets close in 5 hours 17 minutes

Opthea Limited (OPT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.6900-0.0300 (-4.17%)
As of 10:30AM AEST. Market open.
Full screen
Previous close0.7200
Open0.7100
Bid0.6900 x 1566800
Ask0.6950 x 380500
Day's range0.6850 - 0.7150
52-week range0.3125 - 0.8150
Volume251,413
Avg. volume678,956
Market cap457.337M
Beta (5Y monthly)0.73
PE ratio (TTM)N/A
EPS (TTM)-0.4600
Earnings date21 Feb 2024 - 26 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date11 Oct 2004
1y target est7.46
  • Simply Wall St.

    Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT),

    Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...

  • GlobeNewswire

    Opthea Appoints John Han, PharmD, as VP Medical Affairs

    Brings extensive experience in retinal and ophthalmology diseasesMELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective A

  • GlobeNewswire

    Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

    MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024. 23rd Ann